To examine the long-term effect of interferon (IFN) therapy in patients with chronic hepatitis B virus (HBV) infection, particularly on survival and hepatocellular carcinoma (HCC) prevention, 101 male patients with chronic hepatitis B in a randomized controlled trial were followed up for 1.1 to 11.5
Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life
β Scribed by Tadashi Ikeda; Andrew M. L. Lever; Professor Howard C. Thomas
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 406 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
Ninety per cent of patients infected in adult life with the hepatitis B virus clear the virus completely and 10% develop chronic infection. There is evidence for the involvement of interferon in the clearance of acute hepatitis B virus infection. We report that, in in vitro tests, some hepatitis B virus carriers have a reduced capacity to produce a-and y-interferon which is unrelated to the level of viral replication and to the severity of the liver disease and that the level of 2-5 oligoadenylate synthetase in their livers is only minimally elevated compared to controls. Treatment with lymphoblastoid (a-) interferon leads to a marked rise in 2-5 oligoadenylate synthetase activity. These data indicate that some patients with chronic hepatitis B virus infection acquired in adult life have a partial deficiency of production of a-interferon but can respond to exogenous a-interferon. These observations provide a logical basis for attempts to treat this condition with interferons.
π SIMILAR VOLUMES
## Abstract Nineteen Chinese patients with chronic hepatitis B virus (HBV) infection, seropositive for HBV e antigen (HBeAg) and HBV DNA on at least three occasions in 6 months, were randomised to receive either recombinant human interferongamma (rlFNΞ³) 0.1 mg/m^2^ intramuscularly thrice weekly for
Coinfection with hepatitis A virus (HAV) or hepatitis B virus (HBV) in patients with chronic hepatitis C virus (HCV) is associated with increased morbidity and mortality. The Center for Medicare and Medicaid Services has identified HAV and HBV vaccination as a priority area for quality measurement i
## Abstract Infection with hepatitis C virus (HCV) is associated with lymphoproliferative disorders, represented by essential mixed cryoglobulinemia and Bβcell nonβHodgkin's lymphoma, but the pathogenic mechanism remains obscure. HCV may infect B cells or interact with their cell surface receptors,